{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:23Z","timestamp":1792783523185,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Neurelis, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40120-023-00515-3","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T08:02:26Z","timestamp":1687334546000},"page":"1439-1455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Treatment of Seizure Clusters in Epilepsy: A Narrative Review on Rescue Therapies"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4792-8055","authenticated-orcid":false,"given":"Danielle A.","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-3431","authenticated-orcid":false,"given":"James W.","family":"Wheless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-0917","authenticated-orcid":false,"given":"Joseph","family":"Sirven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-3791","authenticated-orcid":false,"given":"William O.","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-0606","authenticated-orcid":false,"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-0722","authenticated-orcid":false,"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"issue":"31","key":"515_CR1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.15585\/mmwr.mm6631a1","volume":"66","author":"MM Zack","year":"2017","unstructured":"Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy\u2014United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"515_CR2","first-page":"1","volume":"57","author":"R Kobau","year":"2008","unstructured":"Kobau R, Zahran H, Thurman DJ, et al. Epilepsy surveillance among adults\u201319 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ. 2008;57(6):1\u201320.","journal-title":"MMWR Surveill Summ"},{"issue":"suppl 1","key":"515_CR3","first-page":"S6","volume":"63","author":"SR Haut","year":"2022","unstructured":"Haut SR, Nabbout R. Recognizing seizure clusters in the community: the path to uniformity and individualization in nomenclature and definition. Epilepsia. 2022;63(suppl 1):S6\u201313.","journal-title":"Epilepsia"},{"key":"515_CR4","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107836","volume":"117","author":"J Buchhalter","year":"2021","unstructured":"Buchhalter J, Shafer PO, Buelow JM, et al. Preferred practices for rescue treatment of seizure clusters: a consensus-driven, multi-stakeholder approach. Epilepsy Behav. 2021;117:107836.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"515_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/WCO.0000000000000177","volume":"28","author":"SR Haut","year":"2015","unstructured":"Haut SR. Seizure clusters: characteristics and treatment. Curr Opin Neurol. 2015;28(2):143\u201350.","journal-title":"Curr Opin Neurol"},{"key":"515_CR6","unstructured":"US Food and Drug Administration. Orphan indications: diazepam (intranasal). https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=382512. Accessed Dec 7, 2021."},{"key":"515_CR7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106748","volume":"177","author":"S Chung","year":"2021","unstructured":"Chung S, Szaflarski JP, Choi EJ, et al. A systematic review of seizure clusters: prevalence, risk factors, burden of disease and treatment patterns. Epilepsy Res. 2021;177:106748.","journal-title":"Epilepsy Res"},{"issue":"2\u20133","key":"515_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2009.08.006","volume":"87","author":"C Martinez","year":"2009","unstructured":"Martinez C, Sullivan T, Hauser WA. Prevalence of acute repetitive seizures (ARS) in the United Kingdom. Epilepsy Res. 2009;87(2\u20133):137\u201343.","journal-title":"Epilepsy Res"},{"issue":"4","key":"515_CR9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/seiz.2000.0499","volume":"10","author":"J Bauer","year":"2001","unstructured":"Bauer J, Burr W. Course of chronic focal epilepsy resistant to anticonvulsant treatment. Seizure. 2001;10(4):239\u201346.","journal-title":"Seizure"},{"key":"515_CR10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yebeh.2015.04.022","volume":"47","author":"RS Fisher","year":"2015","unstructured":"Fisher RS, Bartfeld E, Cramer JA. Use of an online epilepsy diary to characterize repetitive seizures. Epilepsy Behav. 2015;47:66\u201371.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"515_CR11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/NRL.0000000000000140","volume":"22","author":"PE Penovich","year":"2017","unstructured":"Penovich PE, Buelow J, Steinberg K, Sirven J, Wheless J. Burden of seizure clusters on patients with epilepsy and caregivers: survey of patient, caregiver, and clinician perspectives. Neurologist. 2017;22(6):207\u201314.","journal-title":"Neurologist"},{"key":"515_CR12","unstructured":"Epilepsy Foundation. Driving & Transportation. https:\/\/www.epilepsy.com\/lifestyle\/driving-and-transportation. Accessed Apr 13, 2023."},{"issue":"7508","key":"515_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmj.331.7508.60","volume":"331","author":"E Beghi","year":"2005","unstructured":"Beghi E, Sander JW. Epilepsy and driving. BMJ. 2005;331(7508):60\u20131.","journal-title":"BMJ"},{"issue":"suppl 1","key":"515_CR14","first-page":"S14","volume":"63","author":"J Kapur","year":"2022","unstructured":"Kapur J, Long L, Dixon-Salazar T. Consequences: bench to home. Epilepsia. 2022;63(suppl 1):S14\u201324.","journal-title":"Epilepsia"},{"issue":"1","key":"515_CR15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.0013-9580.2005.29004.x","volume":"46","author":"SR Haut","year":"2005","unstructured":"Haut SR, Shinnar S, Moshe SL. Seizure clustering: risks and outcomes. Epilepsia. 2005;46(1):146\u20139.","journal-title":"Epilepsia"},{"issue":"12","key":"515_CR16","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1528-1157.1999.tb01607.x","volume":"40","author":"SR Haut","year":"1999","unstructured":"Haut SR, Shinnar S, Moshe SL, O\u2019Dell C, Legatt AD. The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures. Epilepsia. 1999;40(12):1832\u20134.","journal-title":"Epilepsia"},{"key":"515_CR17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","volume":"813","author":"R Dingledine","year":"2014","unstructured":"Dingledine R, Varvel NH, Dudek FE. When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Adv Exp Med Biol. 2014;813:109\u201322.","journal-title":"Adv Exp Med Biol"},{"key":"515_CR18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.643916","volume":"12","author":"M Ochoa-Urrea","year":"2021","unstructured":"Ochoa-Urrea M, Lacuey N, Vilella L, et al. Seizure clusters, seizure severity markers, and SUDEP risk. Front Neurol. 2021;12:643916.","journal-title":"Front Neurol"},{"issue":"Pt 4","key":"515_CR19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/brain\/awn037","volume":"131","author":"M Sillanpaa","year":"2008","unstructured":"Sillanpaa M, Schmidt D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. Brain. 2008;131(Pt 4):938\u201344.","journal-title":"Brain"},{"issue":"suppl 1","key":"515_CR20","first-page":"S45","volume":"63","author":"E Faught","year":"2022","unstructured":"Faught E. Economic aspects of treating seizure clusters. Epilepsia. 2022;63(suppl 1):S45\u201354.","journal-title":"Epilepsia"},{"issue":"3","key":"515_CR21","doi-asserted-by":"crossref","first-page":"A289","DOI":"10.1016\/j.jval.2015.03.1689","volume":"18","author":"B Vazquez","year":"2015","unstructured":"Vazquez B, Sidovar M, Squillacote D, et al. Healthcare resource utilization associated with rescue medication use in adult patients with seizure clusters: a retrospective chart review. Value Health. 2015;18(3):A289\u201390.","journal-title":"Value Health"},{"issue":"12","key":"515_CR22","first-page":"1576","volume":"26","author":"S Borghs","year":"2020","unstructured":"Borghs S, Beaty S, Parekh W, Kalilani L, Boudiaf N, Loewendorf A. Cost of epilepsy-related health care encounters in the United States. J Manag Care Spec Pharm. 2020;26(12):1576\u201381.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"515_CR23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11940-007-0011-8","volume":"9","author":"JJ Cereghino","year":"2007","unstructured":"Cereghino JJ. Identification and treatment of acute repetitive seizures in children and adults. Curr Treat Options Neurol. 2007;9(4):249\u201355.","journal-title":"Curr Treat Options Neurol"},{"issue":"26","key":"515_CR24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199806253382602","volume":"338","author":"FE Dreifuss","year":"1998","unstructured":"Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338(26):1869\u201375.","journal-title":"N Engl J Med"},{"issue":"4","key":"515_CR25","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/epi.16847","volume":"62","author":"J Cloyd","year":"2021","unstructured":"Cloyd J, Haut S, Carrazana E, Rabinowicz AL. Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia. 2021;62(4):846\u201356.","journal-title":"Epilepsia"},{"key":"515_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2018.05.021","volume":"68","author":"M Gainza-Lein","year":"2019","unstructured":"Gainza-Lein M, Fernandez IS, Ulate-Campos A, Loddenkemper T, Ostendorf AP. Timing in the treatment of status epilepticus: from basics to the clinic. Seizure. 2019;68:22\u201330.","journal-title":"Seizure"},{"issue":"suppl 1","key":"515_CR27","first-page":"S34","volume":"63","author":"B Gidal","year":"2022","unstructured":"Gidal B, Detyniecki K. Rescue therapies for seizure clusters: pharmacology and target of treatments. Epilepsia. 2022;63(suppl 1):S34\u201344.","journal-title":"Epilepsia"},{"key":"515_CR28","unstructured":"Bausch Health US, LLC. Diastat\u00ae C-IV (diazepam rectal gel). Full Prescribing Information. Bausch Health US, LLC; 2023."},{"issue":"6","key":"515_CR29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/1942602X211026333","volume":"36","author":"P Dean","year":"2021","unstructured":"Dean P, O\u2019Hara K, Brooks L, Shinnar R, Bougher G, Santilli N. Managing acute seizures: new rescue delivery option and resources to assist school nurses. NASN Sch Nurse. 2021;36(6):346\u201354.","journal-title":"NASN Sch Nurse"},{"key":"515_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","volume":"68","author":"S Jafarpour","year":"2019","unstructured":"Jafarpour S, Hirsch LJ, Gainza-Lein M, Kellinghaus C, Detyniecki K. Seizure cluster: definition, prevalence, consequences, and management. Seizure. 2019;68:9\u201315.","journal-title":"Seizure"},{"key":"515_CR31","unstructured":"Electronic Medicines Compendium. Diazepam Desitin 5 mg rectal solution. https:\/\/www.medicines.org.uk\/emc\/product\/2997\/smpc. Accessed Sept 8, 2021."},{"key":"515_CR32","unstructured":"Electronic Medicines Compendium. Diazepam RecTubes 10\u00a0mg Rectal Solution. Datapharm Ltd. https:\/\/www.medicines.org.uk\/emc\/product\/6799\/smpc. Accessed Sept 7, 2021."},{"key":"515_CR33","unstructured":"Electronic Medicines Compendium. Stesolid Rectal Tubes 10\u00a0mg. Datapharm Ltd. https:\/\/www.medicines.org.uk\/emc\/product\/104\/smpc. Accessed Sept 10, 2021."},{"key":"515_CR34","unstructured":"Electronic Medicines Compendium. Buccolam 2.5 mg oromucosal solution. https:\/\/www.medicines.org.uk\/emc\/product\/2768\/smpc. Accessed Sept 7, 2021."},{"key":"515_CR35","unstructured":"Neuraxpharm. Neuraxpharm launches first product in Japan. Neuraxpharm. https:\/\/www.neuraxpharm.com\/se\/wp-content\/uploads\/sites\/29\/2021\/04\/en-neuraxpharm-launches-first-product-in-japan.pdf. Accessed Apr 14, 2023."},{"key":"515_CR36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105280","volume":"147","author":"C Stillhart","year":"2020","unstructured":"Stillhart C, Vucicevic K, Augustijns P, et al. Impact of gastrointestinal physiology on drug absorption in special populations\u2013an UNGAP review. Eur J Pharm Sci. 2020;147: 105280.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"515_CR37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1602\/neurorx.2.4.554","volume":"2","author":"MS Alavijeh","year":"2005","unstructured":"Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2(4):554\u201371.","journal-title":"NeuroRx"},{"key":"515_CR38","unstructured":"Hospira, Inc. Midazolam injection (midazolam injection). Full Prescribing Information. Hospira, Inc.; 2023."},{"key":"515_CR39","unstructured":"Neurelis, Inc. VALTOCO\u00ae (diazepam nasal spray). Full Prescribing Information. Neurelis, Inc.; 2023."},{"key":"515_CR40","unstructured":"UCB, Inc. Nayzilam\u00ae (midazolam nasal spray). Full Prescribing Information. UCB,\u00a0Inc.; 2023."},{"issue":"2","key":"515_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/ajem.2002.31573","volume":"20","author":"BK Alldredge","year":"2002","unstructured":"Alldredge BK, Venteicher R, Calderwood TS. Stability of diazepam rectal gel in ambulance-like environments. Am J Emerg Med. 2002;20(2):88\u201391.","journal-title":"Am J Emerg Med"},{"issue":"12","key":"515_CR42","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/archneur.59.12.1915","volume":"59","author":"JJ Cereghino","year":"2002","unstructured":"Cereghino JJ, Cloyd JC, Kuzniecky RI, North American Diastat Study Group. Rectal diazepam gel for treatment of acute repetitive seizures in adults. Arch Neurol. 2002;59(12):1915\u201320.","journal-title":"Arch Neurol"},{"issue":"3","key":"515_CR43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/epi.16449","volume":"61","author":"RE Hogan","year":"2020","unstructured":"Hogan RE, Gidal BE, Koplowitz B, Koplowitz LP, Lowenthal RE, Carrazana E. Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers. Epilepsia. 2020;61(3):455\u201364.","journal-title":"Epilepsia"},{"issue":"5","key":"515_CR44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/WNL.51.5.1274","volume":"51","author":"JJ Cereghino","year":"1998","unstructured":"Cereghino JJ, Mitchell WG, Murphy J, Kriel RL, Rosenfeld WE, Trevathan E. Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The North American Diastat Study Group. Neurology. 1998;51(5):1274\u201382.","journal-title":"Neurology"},{"issue":"11","key":"515_CR45","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1528-1157.1999.tb02047.x","volume":"40","author":"WG Mitchell","year":"1999","unstructured":"Mitchell WG, Conry JA, Crumrine PK, et al. An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance. North American Diastat Group. Epilepsia. 1999;40(11):1610\u20137.","journal-title":"Epilepsia"},{"key":"515_CR46","unstructured":"UCB, Inc. FDA approves shelf life extension for NAYZILAM\u00ae (midazolam) nasal spray, CIV. https:\/\/www.ucb-usa.com\/stories-media\/UCB-U-S-News\/detail\/article\/fda-approves-shelf-life-extension-nayzilam-midazolam-nasal-spray-CIV. Accessed Mar 22, 2022."},{"issue":"11","key":"515_CR47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1111\/epi.13131","volume":"56","author":"LL Bancke","year":"2015","unstructured":"Bancke LL, Dworak HA, Rodvold KA, Halvorsen MB, Gidal BE. Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. Epilepsia. 2015;56(11):1723\u201331.","journal-title":"Epilepsia"},{"key":"515_CR48","volume":"171","author":"MR Bouw","year":"2021","unstructured":"Bouw MR, Chung SS, Gidal B, et al. Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray. Epilepsy Res. 2021;171:106567.","journal-title":"Epilepsy Res"},{"issue":"9","key":"515_CR49","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/epi.15159","volume":"60","author":"K Detyniecki","year":"2019","unstructured":"Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters\u2014a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797\u2013808.","journal-title":"Epilepsia"},{"issue":"9","key":"515_CR50","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/epi.16300","volume":"60","author":"JW Wheless","year":"2019","unstructured":"Wheless JW, Meng TC, Van Ess PJ, Detyniecki K, Sequeira DJ, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial. Epilepsia. 2019;60(9):1809\u201319.","journal-title":"Epilepsia"},{"issue":"11","key":"515_CR51","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/epi.16704","volume":"61","author":"DC Spencer","year":"2020","unstructured":"Spencer DC, Sinha SR, Choi EJ, et al. Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: a double-blind, randomized, placebo-controlled trial. Epilepsia. 2020;61(11):2415\u201325.","journal-title":"Epilepsia"},{"key":"515_CR52","volume":"138","author":"TC Meng","year":"2023","unstructured":"Meng TC, Szaflarski JP, Chen L, et al. Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: results of a phase\u00a03, open-label extension trial. Epilepsy Behav. 2023;138: 108989.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"515_CR53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40268-021-00360-5","volume":"21","author":"AL Rabinowicz","year":"2021","unstructured":"Rabinowicz AL, Carrazana E, Maggio ET. Improvement of intranasal drug delivery with Intravail\u00ae alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system. Drugs R D. 2021;21(4):361\u20139.","journal-title":"Drugs R D"},{"key":"515_CR54","unstructured":"Neurelis Inc. Neurelis announces FDA approval of extended expiration dating for VALTOCO\u00ae (diazepam nasal spray). https:\/\/www.neurelis.com\/neurelis-news\/fda-approval-extended-expiration-dating. Accessed Jan 11, 2022."},{"key":"515_CR55","unstructured":"Neurelis, Inc. Valtoco instructions for use. San Diego, CA: Neurelis, Inc; 2022."},{"key":"515_CR56","unstructured":"US Food and Drug Administration. Valtoco (diazepam nasal spray) NDA Approval. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/211635Orig1s000Approv.pdf. Accessed Oct 28, 2022."},{"key":"515_CR57","unstructured":"US Food and Drug Administration. Clinical Pharmacology Review - Diazepam Nasal Spray. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/211635Orig1s000ClinPharmR.pdf. Accessed Nov 23, 2022."},{"key":"515_CR58","unstructured":"US Food and Drug Administration. Clinical Superiority Findings. https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings. Accessed June 23, 2020."},{"issue":"3","key":"515_CR59","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.eplepsyres.2013.02.018","volume":"105","author":"SK Agarwal","year":"2013","unstructured":"Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105(3):362\u20137.","journal-title":"Epilepsy Res"},{"issue":"6","key":"515_CR60","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/cpdd.767","volume":"9","author":"S Tanimoto","year":"2020","unstructured":"Tanimoto S, Pesco Koplowitz L, Lowenthal RE, Koplowitz B, Rabinowicz AL, Carrazana E. Evaluation of pharmacokinetics and dose proportionality of diazepam after intranasal administration of NRL-1 to healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(6):719\u201327.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"515_CR61","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/epi.16506","volume":"61","author":"RE Hogan","year":"2020","unstructured":"Hogan RE, Tarquinio D, Sperling MR, et al. Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal\/peri-ictal) and nonseizure (interictal) conditions: a phase\u00a01, open-label study. Epilepsia. 2020;61(5):935\u201343.","journal-title":"Epilepsia"},{"issue":"3","key":"515_CR62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1528-1157.1982.tb06198.x","volume":"23","author":"N Milligan","year":"1982","unstructured":"Milligan N, Dhillon S, Oxley J, Richens A. Absorption of diazepam from the rectum and its effect on interictal spikes in the EEG. Epilepsia. 1982;23(3):323\u201331.","journal-title":"Epilepsia"},{"issue":"10","key":"515_CR63","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/epi.17041","volume":"62","author":"JW Wheless","year":"2021","unstructured":"Wheless JW, Miller I, Hogan RE, et al. Final results from a phase\u00a03, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021;62(10):2485\u201395.","journal-title":"Epilepsia"},{"key":"515_CR64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2022.04.011","volume":"132","author":"D Tarquinio","year":"2022","unstructured":"Tarquinio D, Dlugos D, Wheless JW, Desai J, Carrazana E, Rabinowicz AL. Safety of diazepam nasal spray in children and adolescents with epilepsy: results from a long-term phase\u00a03 safety study. Pediatr Neurol. 2022;132:50\u20135.","journal-title":"Pediatr Neurol"},{"key":"515_CR65","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108550","volume":"128","author":"J Wheless","year":"2022","unstructured":"Wheless J, Peters J, Misra SN, et al. Comment on \u201cIntranasal midazolam versus intravenous\/rectal benzodiazepines for acute seizure control in children: a systematic review and meta-analysis.\u201d Epilepsy Behav. 2022;128: 108550.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"515_CR66","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/epi.17177","volume":"63","author":"MR Sperling","year":"2022","unstructured":"Sperling MR, Wheless JW, Hogan RE, et al. Use of second doses of Valtoco\u00ae (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: results from a phase\u00a03, open-label, repeat-dose safety study. Epilepsia. 2022;63(4):836\u201343.","journal-title":"Epilepsia"},{"key":"515_CR67","unstructured":"Tarquinio D, Hogan RE, Sperling MR, et al. Safety and effectiveness of diazepam nasal spray in pediatric patients with epileptic encephalopathy: final results from a phase\u00a03, open-label, repeat-dose safety study [poster #2.213]. Presented at: American Epilepsy Society, December 3\u20137, 2021; Chicago."},{"issue":"Pt A","key":"515_CR68","volume":"121","author":"P Penovich","year":"2021","unstructured":"Penovich P, Wheless JW, Hogan RE, et al. Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: results from an exit survey of a phase\u00a03, open-label, repeat-dose safety study. Epilepsy Behav. 2021;121(Pt A): 108013.","journal-title":"Epilepsy Behav"},{"key":"515_CR69","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108811","volume":"134","author":"JA Cramer","year":"2022","unstructured":"Cramer JA, Faught E, Davis C, Misra SN, Carrazana E, Rabinowicz AL. Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study. Epilepsy Behav. 2022;134: 108811.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"515_CR70","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/epi.17385","volume":"63","author":"SN Misra","year":"2022","unstructured":"Misra SN, Sperling MR, Rao VR, et al. Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters. Epilepsia. 2022;63(10):2684\u201393.","journal-title":"Epilepsia"},{"issue":"8","key":"515_CR71","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/epi.16279","volume":"60","author":"JA French","year":"2019","unstructured":"French JA, Wechsler R, Gelfand MA, et al. Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants. Epilepsia. 2019;60(8):1602\u20139.","journal-title":"Epilepsia"},{"key":"515_CR72","unstructured":"ClinicalTrials.gov. A study to test the safety and tolerability of staccato alprazolam in study participants 12 years of age and older with stereotypical prolonged seizures. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05076617. Accessed Jan 27, 2022."},{"key":"515_CR73","unstructured":"ClinicalTrials.gov. A study to test the efficacy and safety of staccato alprazolam in study participants 12 years of age and older with stereotypical prolonged seizures. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05077904. Accessed Jan 27, 2022."},{"key":"515_CR74","unstructured":"ClinicalTrials.gov. Safety and tolerability study of diazepam buccal film (DBF) in subjects with epilepsy (DBF). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03428360. Accessed Apr 20, 2023."},{"issue":"11","key":"515_CR75","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/epi.16696","volume":"61","author":"S Seinfeld","year":"2020","unstructured":"Seinfeld S, Gelfand MA, Heller AH, Buan C, Slatko G. Safety and tolerability associated with chronic intermittent use of diazepam buccal film in adult, adolescent, and pediatric patients with epilepsy. Epilepsia. 2020;61(11):2426\u201334.","journal-title":"Epilepsia"},{"key":"515_CR76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2020.12.006","volume":"85","author":"D Ertan","year":"2021","unstructured":"Ertan D, Hubert-Jacquot C, Maillard L, et al. Anticipatory anxiety of epileptic seizures: an overlooked dimension linked to trauma history. Seizure. 2021;85:64\u20139.","journal-title":"Seizure"},{"issue":"7","key":"515_CR77","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/epi.17249","volume":"63","author":"GD Cascino","year":"2022","unstructured":"Cascino GD, Tarquinio D, Wheless JW, et al. Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: a population analysis. Epilepsia. 2022;63(7):1714\u201323.","journal-title":"Epilepsia"},{"key":"515_CR78","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.2147\/NDT.S376104","volume":"18","author":"AL Rabinowicz","year":"2022","unstructured":"Rabinowicz AL, Faught E, Cook DF, Carrazana E. Implications of seizure-cluster treatment on healthcare utilization: use of approved rescue medications. Neuropsychiatr Dis Treat. 2022;18:2431\u201341.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"suppl 1","key":"515_CR79","first-page":"S25","volume":"63","author":"AD Patel","year":"2022","unstructured":"Patel AD, Becker DA. Introduction to use of an acute seizure action plan for seizure clusters and guidance for implementation. Epilepsia. 2022;63(suppl 1):S25\u201333.","journal-title":"Epilepsia"},{"issue":"8","key":"515_CR80","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3390\/jcm10081754","volume":"10","author":"S Almohaish","year":"2021","unstructured":"Almohaish S, Sandler M, Brophy GM. Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med. 2021;10(8):1754.","journal-title":"J Clin Med"},{"key":"515_CR81","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3389\/fphar.2019.01196","volume":"10","author":"S Hua","year":"2019","unstructured":"Hua S. Physiological and pharmaceutical considerations for rectal drug formulations. Front Pharmacol. 2019;10:1196.","journal-title":"Front Pharmacol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00515-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:15:41Z","timestamp":1692706541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00515-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00515-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}